Vaccine development for group A streptococcus infections and associated disease
Related Experiment Video
Updated: Aug 29, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
M R Batzloff1, K S Sriprakash, M F Good
1Cooperative Research Centre for Vaccine Technology, The Australian Centre for International Tropical Health and Nutrition, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane 4029, Australia. michaeBa@qimr.edu.au
Abstract:
Group A streptococcus (GAS) is responsible for a number of diseases ranging from uncomplicated pharyngitis through to life-treating invasive and post-infectious diseases such as necrotizing fasciitis and rheumatic heart disease. GAS associated diseases occur globally and are serious problems in many developing nations and indigenous populations of many developed nations. This, and the resurgence in industrialized countries, and increased virulence of GAS in the 1980s highlight the need of cost-effective control strategies. Here we highlight the GAS diseases that are still a problem in many populations and discuss potentially useful strategies to combat GAS infections and disease.
Related Concept Videos
Streptococcal Pharyngitis
Staphylococcal Skin Infections
Rheumatic Heart Disease III: Medical Management
Determinants of Bacterial Pathogenicity and Virulence
Microorganisms in Medicine and Therapeutics
Clinical Significance of Antibiotic Resistance
